Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegaptanib sodium
- Development stage
- Phase 4
- Lead developer
- Astellas Pharma
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal, Ophthalmic
01
Overview
Pegaptanib sodium is a pegylated RNA aptamer and selective vascular endothelial growth factor (VEGF) antagonist used for the treatment of neovascular (wet) age-related macular degeneration (AMD). It is a covalent conjugate of a 28-nucleotide oligonucleotide linked to two polyethylene glycol (PEG) units. Pegaptanib specifically binds to the VEGF165 isoform, inhibiting its interaction with VEGF receptors on vascular endothelial cells. This action blocks angiogenesis and reduces vascular permeability in the eye, thereby controlling abnormal blood vessel growth and leakage associated with wet AMD. Pegaptanib was originally discovered by NeXstar Pharmaceuticals (later merged with Gilead Sciences), further developed by Eyetech Pharmaceuticals/OSI Pharmaceuticals in the US, and marketed outside the US by Pfizer[1][3][4][6].
- Brand names
- Macugen
- Other names
- pegaptanibpegaptanib octasodiumanti-VEGF aptamer
02
Targets
Beyond the preview
Go deeper on pegaptanib sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegaptanib sodium.